G-1 (CAS 881639-98-1): Selective GPR30 Agonist for Cardiovascular and Breast Cancer Research

Executive Summary: G-1 (CAS 881639-98-1) is a potent and selective agonist for the G protein-coupled estrogen receptor GPR30/GPER1, with a Ki of ~11 nM and negligible activity at classical ERα/ERβ even at high concentrations (APExBIO). G-1 triggers rapid intracellular signaling, notably calcium mobilization (EC50 = 2 nM) and PI3K-PIP3 nuclear accumulation, leading to effects such as inhibition of breast cancer cell migration and attenuation of cardiac fibrosis in rat models (Wang et al., 2021). Distinct from genomic estrogen signaling, G-1 enables researchers to isolate non-nuclear estrogenic effects, providing clarity in cardiovascular, endocrine, and oncology research (GTP Solution). Its solubility profile, storage requirements, and validated experimental benchmarks make it an essential reagent for dissecting GPR30 pathways. This article contextualizes G-1’s applications, current evidence, and integration strategies for translational biology.

Biological Rationale

GPR30 (also known as GPER1) is a membrane-bound estrogen receptor distinct from the nuclear ERα and ERβ. It mediates rapid, non-genomic estrogen signaling, influencing calcium flux, PI3K activity, and downstream gene expression (Wang et al., 2021). GPR30 is expressed in cardiovascular tissue, breast epithelium, and immune cells. Rapid estrogen signaling via GPR30 has been implicated in the regulation of cardiac contractility, inhibition of cardiac fibrosis, immune cell homeostasis, and suppression of breast cancer cell migration. G-1 was developed to enable specific probing of these pathways by activating GPR30 without cross-reactivity to nuclear estrogen receptors (APExBIO). This selectivity allows for mechanistic dissection of GPR30-mediated effects versus classical estrogen signaling, which is often confounded by the dual activity of endogenous and synthetic estrogens. For extended background on GPR30 biology and translational impact, see Strategic Frontiers in GPR30 Activation—this article updates those insights with new quantitative benchmarks and workflow guidance.

Mechanism of Action of G-1 (CAS 881639-98-1), a selective GPR30 agonist

G-1 binds GPR30/GPER1 with high affinity (Ki ~11 nM), triggering conformational changes and intracellular signaling cascades (APExBIO). It does not bind ERα or ERβ at concentrations up to 10 μM, ensuring specificity. Upon activation, GPR30 induces intracellular calcium elevation (EC50 = 2 nM), PI3K activation, and nuclear accumulation of phosphatidylinositol (3,4,5)-trisphosphate (PIP3) (Wang et al., 2021). These events result in downstream modulation of gene expression, cytoskeletal rearrangement, and functional changes in cell migration, proliferation, and survival. In heart failure models, G-1 normalizes β1-adrenergic receptor levels and upregulates β2-adrenergic receptor expression, contributing to improved cardiac contractility and reduced fibrosis. In breast cancer cell lines, G-1 inhibits cell migration with IC50 values of 0.7 nM (SKBr3) and 1.6 nM (MCF7), indicating potent anti-migratory effects through GPR30 pathway activation. For a mechanistic comparison, see Strategic Frontiers in GPR30 Biology; this article provides updated specificity data and workflow integration recommendations.

Evidence & Benchmarks

• G-1 exhibits high binding affinity for GPR30 (Ki ~11 nM) with minimal off-target binding to ERα/ERβ at up to 10 μM concentrations (APExBIO).
• Activation of GPR30 by G-1 elevates intracellular calcium with an EC50 of 2 nM in in vitro assays (Wang et al., 2021, Fig. 1).
• G-1 inhibits migration of SKBr3 breast cancer cells (IC50 = 0.7 nM) and MCF7 cells (IC50 = 1.6 nM) in transwell assays (APExBIO).
• In vivo, chronic G-1 administration reduces cardiac fibrosis and brain natriuretic peptide levels in ovariectomized female Sprague-Dawley rats with heart failure, while improving cardiac contractility (Wang et al., 2021).
• Beneficial immune effects of estradiol in post-hemorrhagic shock rats are mediated through ERα and GPR30, but not ERβ, as shown by selective agonists/antagonists and G-1’s recapitulation of immune normalization (Wang et al., 2021).
• G-1 is insoluble in water and ethanol, but dissolves in DMSO at ≥41.2 mg/mL; recommended for experimental stock solutions at >10 mM and stored at -20°C (APExBIO).

These benchmarks are consistent with prior reviews and thought-leadership articles, but this synthesis adds quantitative reference points for practitioners (Akt Antibody Article—this article clarifies mechanistic distinctions between PI3K and calcium pathways).

Applications, Limits & Misconceptions

Applications:

• Dissection of rapid, non-genomic estrogen signaling in cardiovascular and breast cancer models.
• Evaluation of GPR30's role in immune normalization post-hemorrhagic shock (Wang et al., 2021).
• Analysis of PI3K and calcium-dependent signaling in estrogen-responsive tissues.
• Tool for validating pharmacological selectivity in GPR30-related screening or target validation workflows (APExBIO).

Common Pitfalls or Misconceptions:

• G-1 is not a pan-estrogen receptor agonist; it does not activate nuclear ERα or ERβ at relevant concentrations.
• G-1 is not water- or ethanol-soluble; inappropriate solvent use may lead to precipitation or poor bioavailability in vitro or in vivo (APExBIO).
• Long-term storage of G-1 solutions is not recommended; repeated freeze-thaw cycles can degrade compound integrity.
• Interpretation of G-1 effects in mixed cell systems requires confirmation of GPR30 expression, as off-targets at supraphysiologic doses are not fully excluded.
• G-1’s effects should not be equated with those of endogenous estrogens, which act via multiple receptors and pathways.

Workflow Integration & Parameters

• Prepare G-1 stock solutions in DMSO at concentrations >10 mM; warming and ultrasonic bath can enhance dissolution.
• Store stock solutions at -20°C; avoid repeated freeze-thaw cycles.
• Recommended in vitro working concentrations are typically in the 1–100 nM range, consistent with reported EC50 and IC50 values for GPR30-dependent endpoints (Wang et al., 2021).
• For in vivo use, dosing regimens should be based on published models, such as chronic administration in ovariectomized female Sprague-Dawley rats (see Wang et al., 2021).
• Confirm GPR30/GPER1 expression in target cells or tissues by qPCR or immunostaining.
• Include appropriate controls: vehicle (DMSO), ERα/ERβ agonists/antagonists, and GPR30 antagonists (e.g., G15) to validate pathway specificity.

Researchers seeking a complete kit or lot-specific documentation can refer to the B5455 kit from APExBIO.

Conclusion & Outlook

G-1 (CAS 881639-98-1) is an established, selective GPR30 agonist enabling precise dissection of rapid estrogen signaling in cardiovascular, immune, and breast cancer research. Its nanomolar potency, well-characterized specificity, and robust solubility profile underpin its status as a benchmark reagent. With emerging evidence supporting GPR30’s role in immune modulation and cardioprotection, G-1 is positioned to catalyze new discoveries in disease models where non-genomic estrogen signaling is relevant. For further strategic insights and future directions, see Strategic Frontiers in GPR30 Activation: G-1 (CAS 881639-98-1)—this article provides updated experimental guidelines and workflow integration tips for advanced users.